Randomized Controlled Trial of Bladder Flap vs.None

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Mountain Area Health Organization Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Mountain Area Health Organization Center
ClinicalTrials.gov Identifier:
NCT00470288
First received: May 4, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

Objective: To compare outcomes in cesarean section patients undergoing bladder flap versus none. Hypotheses: Operative time will be reduced with the elimination of a bladder flap during cesarean delivery and intra-operative and post-operative morbidity will not be significantly different.

Patients >= 35 wks gestation undergoing cesarean delivery will be randomized to bladder flap vs. none. Primary outcome is operative time (start to delivery); secondary outcomes include: injuries, EBL, intra-operative and post-operative complications,pain medication, hospital stay duration.


Condition Intervention
Cesarean Delivery Procedures
Procedure: bladder flap during cesarean section

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of Bladder Flap vs.None

Resource links provided by NLM:


Further study details as provided by Mountain Area Health Organization Center:

Primary Outcome Measures:
  • operative time: start of surgery to delivery of infant [ Time Frame: immediate: during cesarean surgery ]

Secondary Outcome Measures:
  • estimated blood loss [ Time Frame: immediate ]
  • bladder injuries [ Time Frame: immediate ]
  • other intra-operative complications [ Time Frame: immediate ]
  • intra-operative transfusions [ Time Frame: immediate ]
  • post-operative complications [ Time Frame: post-op hospitalization ]
  • medication use: antibiotics and narcotics [ Time Frame: post-op hospitalization ]
  • duration of post-op hospitalization [ Time Frame: post-op hospitalization ]
  • readmisison post discharge [ Time Frame: 6 weeks post-op ]

Estimated Enrollment: 123
Study Start Date: October 2005
Estimated Study Completion Date: June 2007
  Hide Detailed Description

Detailed Description:
  1. Title A Randomized Controlled Trial of Bladder Flap vs. None in Cesarean Section
  2. Background (This section should be used to provide a rationale for the conduct of the study. Refer to existent or preliminary studies as necessary) The standard of care in performing cesarean delivery is to perform a bladder flap in the procedures.1 The creation of a bladder flap essentially allows a surgeon to create a space between the uterus and the bladder so that he/she has better access to the lower portion of the uterus where a low transverse incision can be made. This procedure involves making a superficial incision into the peritoneum, or the cell lining of the abdominal cavity, and the moving the bladder down and away from the lower portion of the uterus. A retractor or a bladder blade is then inserted into this space to hold the bladder away from the uterus (see Appendix A).2 Use of the bladder flap in cesarean delivery dates back to 1878 in the pre-antibiotic era,3 and theoretically, the bladder flap allows better access to the low portion of the uterus while decreasing risk of bladder injury and infection. However, several recent but small studies suggest the inclusion of the bladder flap confers no advantage and may actually contribute to greater morbidity postoperatively. 4-5 Additionally, the incidence of bladder injuries is 0.3%, and most injuries resulted during the formation of the bladder flap.6 The evidence from these studies are limited by the inclusion of other modifications in surgical procedures and a lack of replication of results, respectively. Thus there is insufficient evidence to either support or reject the inclusion of bladder flaps in cesarean deliveries (Evidence grade C).7-8
  3. Specific Objectives (Enumerate the objectives and nature of the measured end-points. Justify the use of surrogate clinical end-points as necessary)

1. To compare outcomes in cesarean section patients undergoing bladder flap versus none.

4. Study design (Explicate the nature of the study – observational vs experimental. Differentiate between cohort, case-control, and cross-sectional and randomized clinical trials. For the latter, provide sufficient supporting justification for the experimental arm. If it is a placebo-controlled trial, please state whether clinical equipoise exists between the placebo and experimental arm.) Randomized controlled trial.

Endpoints:

Total operating time (continuous) and Time of delivery to end of surgery (continuous) Estimated blood loss (continuous) Post operative fever (categorical) Bladder injury (categorical) Pre- and post-operative pain medication (continuous) and Analog pain scale (continuous)

5. Subject Selection (Include an enumeration of inclusion and exclusion criteria)

MAHEC patients presenting for delivery at Mission Hospitals requiring a cesarean section

Inclusion Exclusion Cesarean section All vaginal deliveries

≥ 35 weeks gestation < 35 weeks gestation Able to provide consent for medical treatment Urgent cesarean section Unable to provide consent for medical treatment Medical complications prohibitive of bladder flap Medical complications prohibitive of no bladder flap

6. Statistical methods, data analysis and interpretation (Include the factors considered in determining an appropriate sample size) Sample size of 100 per group based on an estimated mean difference of 5 minutes on total operating time (study arm 45±12.5 vs. bladder flap arm 50±12.5; Power=080; alpha=0.05; two-tailed).4

Per protocol analysis utilizing analysis of variance or for continuous variables and chi square analysis of categorical variables.

7. Study Procedures (Describe the chronological flow of the study, using schematic diagrams as necessary. Distinguish clearly between treatment-related [medically-indicated] and research-related procedures the subject will undergo)

All OB patients presenting at L&D for delivery will be approached for informed consent. consenting patients for whom a cesarean delivery is medically indicated will be randomized to bladder flap vs. none. Patients unable to consent for medical treatment or not wishing to consent for the project will be excluded. Consenting patients for whom a cesarean is medically indicated will be randomly assigned to bladder flap vs. by previously allocation of subject number. Patients will undergo assigned procedure unless excluded at the discretion of the surgeons who determine the alternate procedure is medically indicated. Patients undergoing the assigned procedure will have all data extracted from hospital medical records and entered into SPSS for a per-protocol analysis.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Cesarean delivery at >=35 weeks gestation;
  • Able to provide informed consent

Exclusion Criteria:

  • Vaginal delivery;
  • Delivery < 35 weeks gestation;
  • STAT surgery;
  • Unable to provide consent;
  • Medical complication/condition incompatable with random asiignment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470288

Contacts
Contact: Eric C Helms, MD 828-771-5501 Eric.helms@mahec.net
Contact: Shelley L Galvin, MA 828-771-5501 Shelley.Galvin@mahec.net

Locations
United States, North Carolina
Mission Hospitals Recruiting
Asheville, North Carolina, United States, 28801
Sponsors and Collaborators
Mountain Area Health Organization Center
Investigators
Principal Investigator: Eric C Helms, MD MAHEC OB/GYN
Study Director: Shelley L Galvin, MA MAHEC OB/GYN
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00470288     History of Changes
Other Study ID Numbers: 05-10-477
Study First Received: May 4, 2007
Last Updated: May 4, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Mountain Area Health Organization Center:
cesarean delivery
bladder flaps

ClinicalTrials.gov processed this record on July 22, 2014